CyberArk Software, Ltd. (NASDAQ:CYBR) represented a move of 1.5 percent or $-0.44 per share and closed its previous day trading session at $45.35. 789563 Shares were traded in the last trading session with an Average Volume of 468.28 Million Shares. The stock currently has a Market Capitalization of 1.59 Billion.
CyberArk Software Ltd. provides information technology security solutions. The Company offers services which protect organizational privileged accounts from cyber-attacks. Its products include CyberArk Shared Technology Platform, Privileged Account Security Solution and Sensitive Information Management Solution. The company offers privileged account security solution consists of enterprise password vault, which provides a tool to manage and protect physical, virtual, or cloud-based assets in an organization; privileged session manager that protects IT assets; and application identity manager, which addresses the challenges of hard-coded, embedded credentials, and cryptographic keys being hijacked and exploited by malicious insiders or external cyber attackers. CyberArk Software Ltd. is headquartered in Petach Tikva, Israel.
The stock traded between $39.34 and $55.63 over 1-Year time period showing its price to sales ratio of 6.46. CyberArk Software, Ltd. (NASDAQ:CYBR) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $5.27 and 200-Day Simple Moving Average of $1.89. Its Price to Free Cash Flow is 26.22 and Price to Book of 4.62.
Analyst’s recommended the stock as 2.3 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, CyberArk Software, Ltd. (NASDAQ:CYBR) reported its Actual EPS of $0.25/share. The analysts offering Earnings Estimates for the company were believing that CyberArk Software, Ltd. could bring EPS of $0.19/share. The difference between Actual EPS and Estimated EPS was 0.06 Percent. Thus showing an Earnings Surprise of 31.6 Percent.
Agenus Inc. (NASDAQ:AGEN)
In the last trading session, Agenus Inc. (NASDAQ:AGEN) added its value by 2.13% closing at the price of $3.84. The stock currently has market capitalization of 339.61 Million, with average volume of 1.13 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Agenus Inc. (NASDAQ:AGEN) is showing beta of 1.72. This particular value of beta suggests that Agenus Inc. (NASDAQ:AGEN) has historically moved 172% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Agenus Inc. (NASDAQ:AGEN) is at $-1.17.
The stock currently has RSI of 55.5. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company’s product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Agenus Inc. (NASDAQ:AGEN) topped its 52-week high price of $5.45 on 07/25/17 and 52-Week Low Price of $3.20 on 04/11/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 5.21% and monthly volatility of 4.93% respectively.